Mylan set to launch $27.1 billion hostile bid for Perrigo on September 14

9 September 2015
mergers-acquisitions-big

Netherlands-incorporated generic drugmaker Mylan (Nasdaq: MYL) said it will launch a $27.1 billion hostile takeover bid for the Ireland-based company Perrigo.

So far the generics company Perrigo has turned down a string of offers from Mylan. The August offer was rejected with Perrigo recently saying that it undervalued the company.

Under the new deal Mylan is offering $75 in cash and 2.3 shares of its own stock for every Perrigo share, valuing Perrigo at about $185.52 per share, based on its closing price on September 4.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics